Physician profile
Jonathan Paramo
NPI 1013303015
$459.99
in general payments reported to CMS, 2019-2025
11 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $34.87 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.41 | 2025 | |
| Janssen Biotech, INC. | $61.41 | 2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $60.61 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $53.62 | 2025 | Prolia, Evenity, Tavneos |
| Ucb, INC. | $50.56 | 2025 | Bimzelx |
| Glaxosmithkline, LLC. | $38.00 | 2024-2025 | Benlysta |
| Genentech USA, INC. | $33.77 | 2025 | Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $33.49 | 2025 | |
| Mallinckrodt Hospital Products INC. | $30.26 | 2025 | Acthar |
| Janssen Pharmaceuticals, INC | $21.29 | 2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $14.57 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Paramo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.